CM
SPRY icon

Caption Management’s ARS Pharmaceuticals SPRY Stock Holding History

Caption Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,812
Closed -$300K – 2035
2025
Q3 		$300K Buy
+29,812
New +$428K ﹤0.01% 1407
2024
Q4 		– Sell
-64,700
Closed -$938K – 1808
2024
Q3 		$938K Buy
+64,700
New +$770K 0.02% 795
2023
Q3 		– Sell
-73,400
Closed -$492K – 1530
2023
Q2 		$492K Buy
+73,400
New +$490K 0.01% 824

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's SPRY Position: Q4 2025 in Review

Caption Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 29,812 shares — an estimated $300K sold.

Caption Management first reported a position in SPRY in Q2 2023 and held it in 3 quarters. The position peaked at $938K in Q3 2024. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Caption Management reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 29,812 ARS Pharmaceuticals shares in Q4 2025, an estimated $300K.
  • Caption Management first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Caption Management's ARS Pharmaceuticals position peaked at $938K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.